Dr. Debu Tripathy on Molecular Predictors of Outcome in Breast Cancer

Debu Tripathy, MD
Published: Thursday, Jan 28, 2016



Debu Tripathy, MD, professor of Medicine, chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses molecular predictors of outcome for patients with ER-positive breast cancer.

A recent analysis found potential genes and gene patterns that may predict breast cancer recurrence within the first 5 years of treatment, explains Tripathy.

Currently, the Oncotype DX test is used to predict recurrence, but specific pathways may help oncologists understand recurrence risk better, says Tripathy. It is too early to apply this analysis, as results will have to be validated. However, it is a step in the right direction, he says.

SELECTED
LANGUAGE


Debu Tripathy, MD, professor of Medicine, chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses molecular predictors of outcome for patients with ER-positive breast cancer.

A recent analysis found potential genes and gene patterns that may predict breast cancer recurrence within the first 5 years of treatment, explains Tripathy.

Currently, the Oncotype DX test is used to predict recurrence, but specific pathways may help oncologists understand recurrence risk better, says Tripathy. It is too early to apply this analysis, as results will have to be validated. However, it is a step in the right direction, he says.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x